Studies by Julia et al. and Facchetti et al. demonstrated that having CD4+, CD 56+, CD123+, and TCL-1-expressing cells, would prove to be reliable when making the diagnosis of BPDCN [17,22]. Here, CD4 is linked to CD4+/CD56+ hematodermic neoplasm.